olivLaw · US equity research
Prime Medicine, Inc. PRME
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Prime Medicine is a biotechnology company developing genetic therapies based on Prime Editing, a technology that rewrites DNA without making double-stranded breaks. The company is nearing its first clinical entries for programs in Wilson disease and alpha-1 antitrypsin deficiency, and its liquidity, of $108.8 million as of June 30, 2026, provides runway into 2027, which makes the coming period decisive.
At the close of 04 Nov 2026, Prime Medicine, Inc. (PRME) stock was 4.97 USD (+9.23% on the day), with market capitalisation 901.4 m USD, beta 2.23, 52-week range 2.70–5.36 USD. Latest reported quarter (Q2 2026): net income of -42.1 m USD, diluted EPS -0.24 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 62.9
- strong (55–70)
- Bollinger (20, 2)
- 2.80 – 5.30
- in the upper half of the band · %B 0.87 · band width 61.8%
- SMA 50 / 200
- 3.61 / 3.50
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.38 / 0.30
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +54.8% | −2.0% | +56.8 pp | — |
| 3 months | +61.4% | −2.2% | +63.5 pp | — |
| 6 months | +45.7% | +4.3% | +41.5 pp | — |
| Year to date | +44.5% | +10.6% | +33.9 pp | — |
| 1 year | +15.6% | +10.5% | +5.1 pp | −3.8% |
| 3 years | −36.3% | +73.7% | −109.9 pp | +18.6% |
| 5 years | unavailable | +61.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 209.0 k | 2.2 m | 1.5 m | 1.1 m | 1.2 m | 838.0 k | — | — |
| Research & development | 40.3 m | 34.1 m | 40.6 m | 41.4 m | 44.0 m | 34.7 m | 34.1 m | 33.4 m |
| Operating income | -54.2 m | -44.2 m | -52.4 m | -53.4 m | -54.0 m | -48.6 m | -50.7 m | -43.3 m |
| Depreciation & amortisation | 1.6 m | 1.7 m | 1.7 m | 1.9 m | 1.9 m | 1.9 m | 1.9 m | 1.8 m |
| Income tax | 0 | 0 | 0 | 0 | — | — | — | — |
| Net income | -52.5 m | -42.3 m | -51.9 m | -52.6 m | -50.6 m | -46.1 m | -49.1 m | -42.1 m |
| Diluted EPS | -0.44 | -0.32 ≈ | -0.40 | -0.41 | -0.32 | -0.26 ≈ | -0.28 | -0.24 |
| Operating cash flow | -25.9 m ≈ | 16.2 m | -48.9 m | -41.4 m ≈ | -35.0 m ≈ | -37.3 m | -42.7 m | -41.0 m ≈ |
| Capex | 1.3 m ≈ | 1.8 m | 2.4 m | 1.6 m ≈ | 247.0 k ≈ | 290.0 k | 214.0 k | 46.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 5.2 m | 0 | 0 | 0 | 3.0 m | 4.6 m |
| Revenue YoY | unavailable | −100.0% | unavailable | unavailable | unavailable | +55.3% |
| Net income | -3.4 m | -165.4 m | -121.8 m | -198.1 m | -195.9 m | -201.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -1.91 | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -65.5% | unavailable | unavailable | unavailable | -6,566.6% | -4,342.4% |
| Free cash flow | -6.2 m | -38.2 m | -147.9 m | -174.1 m | -130.2 m | -167.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 63.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 120.9 m USD
- Total assets
- 342.7 m USD
- Debt / equity
- unavailable
- Current ratio
- 4.84x
- ROE
- -146.8%
- ROA
- -62.8%
- FCF margin
- -3,607.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 5.2 m | 0 | 0 | 0 | 3.0 m | 4.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Research & development | 3.0 m | 70.6 m | 86.7 m | 147.9 m | 155.3 m | 160.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Operating income | -932.0 k | -84.5 m | -116.5 m | -204.8 m | -202.5 m | -208.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Depreciation & amortisation | 43.0 k | 568.0 k | 2.2 m | 4.7 m | 6.1 m | 7.3 m | SEC (XBRL)· 03 Mar 2026verified |
| EBITDA | -889.0 k ≈ | -83.9 m ≈ | -114.3 m ≈ | -200.1 m ≈ | -196.3 m ≈ | -201.0 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Income tax | 1.9 m | -486.0 k | -948.0 k | -279.0 k | 0 | 0 | SEC (XBRL)· 03 Mar 2026verified |
| Net income | -3.4 m | -165.4 m | -121.8 m | -198.1 m | -195.9 m | -201.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Diluted EPS | -1.91 | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 | SEC (XBRL)· 03 Mar 2026verified |
| Weighted average diluted shares | 2.6 m | 13.0 m | 33.9 m | 91.0 m | 118.6 m | 148.8 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 37.0 m | 185.4 m | 187.6 m | 41.6 m | 182.5 m | 63.0 m | SEC (XBRL)· 03 Mar 2026verified |
| Current assets | — | 270.6 m | 296.6 m | 143.0 m | 211.9 m | 181.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Property, plant & equipment, net | — | 4.9 m | 19.0 m | 22.7 m | 24.4 m | 20.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Total assets | — | 301.9 m | 360.3 m | 193.9 m | 297.5 m | 342.7 m | SEC (XBRL)· 03 Mar 2026verified |
| Accounts payable | — | 1.4 m | 4.3 m | 19.5 m | 11.4 m | 8.9 m | SEC (XBRL)· 03 Mar 2026verified |
| Current liabilities | — | 58.0 m | 26.7 m | 56.4 m | 38.0 m | 37.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Total liabilities | — | 62.3 m | 44.0 m | 60.8 m | 144.4 m | 221.9 m | SEC (XBRL)· 03 Mar 2026verified |
| Equity | 2.3 m † | -156.2 m † | 316.3 m † | 133.1 m † | 153.1 m † | 120.9 m † | SEC (XBRL)· 03 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.5 m | -34.1 m | -131.8 m | -165.4 m | -122.9 m | -162.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Capex | 639.0 k | 4.2 m | 16.1 m | 8.7 m | 7.3 m | 4.5 m | SEC (XBRL)· 03 Mar 2026verified |
| Free cash flow | -6.2 m ≈ | -38.2 m ≈ | -147.9 m ≈ | -174.1 m ≈ | -130.2 m ≈ | -167.1 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Investing cash flow | -1.1 m | -73.6 m | -47.1 m | 18.7 m | 68.5 m | -108.8 m | SEC (XBRL)· 03 Mar 2026verified |
| Financing cash flow | 34.9 m | 269.3 m | 181.5 m | 655.0 k | 195.9 m | 151.5 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 18.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 901.4 m USD
Key indicators
Coverage and freshness
Score by group
19% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -4,056.4% | 10 (vs peers) | 33% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 3.1x | 100 (on a fixed band) | 22% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -17.4% | 0 (on a fixed band) | 44% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial10/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Prime Medicine, Inc. (PRME). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 4.6 m USD in 2025; YoY growth 55.3%; net margin -4,056.4%; ROE -373.3%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 18.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 3.1x
What contradicts it
- Net margin: -4,056.4%
- FCF yield: -17.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 249.4 bn | 28.7 | 91.5% | 23.0% | +10.0% | +34% / +71% |
| GILDGilead Sciences, Inc. | 207.7 bn | — | -22.3% | -12.5% | +2.4% | +33% / +119% |
| MRNAModerna, Inc. | 91.2 bn | — | -39.0% | -141.4% | −39.9% | +779% / +194% |
| RVMDRevolution Medicines, Inc. | 41.6 bn | — | -79.1% | — | unavailable | +150% / +733% |
| BIIBBiogen Inc. | 36.8 bn | 106.4 | 1.9% | 3.4% | +2.2% | +37% / +6% |
| MESOMesoblast Limited | 18.5 bn | — | -19.0% | -593.9% | +191.4% | −17% / +425% |
| EXELExelixis, Inc. | 17.6 bn | 21.6 | 44.3% | 35.5% | +7.0% | +64% / +232% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| TWSTTwist Bioscience Corporation | 8.9 bn | — | -29.6% | -31.7% | +20.3% | +345% / +493% |
| SCNIScinai Immunotherapeutics Ltd. | 6.2 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| CGONCG Oncology, Inc. | 6.0 bn | — | -26.4% | -3,602.7% | +254.7% | +51% / unavailable |
| TARSTarsus Pharmaceuticals, Inc. | 3.4 bn | — | -319.8% | -102.9% | +146.7% | −14% / +318% |
| DNLIDenali Therapeutics Inc. | 3.4 bn | — | -33.9% | -1,470.5% | unavailable | +8% / +13% |
| ADMAAdma Biologics, Inc. | 2.3 bn | 14.9 | 41.9% | 33.0% | +19.6% | −45% / +183% |
| VCELVericel Corporation | 2.3 bn | 107.7 | 7.2% | 7.9% | +16.5% | +13% / +28% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -40.9% | +94.1% | +15% / +40% |
| VIRVir Biotechnology, Inc. | 2.0 bn | — | -26.1% | -83.0% | −7.6% | +83% / +24% |
| ALVOAlvotech | 1.5 bn | 46.7 | — | 4.8% | +19.7% | −8% / −51% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| PRMEPrime Medicine, Inc. | 901.4 m | — | -373.3% | -4,056.4% | +55.3% | +16% / −36% |
| CADLCandel Therapeutics, Inc. | 692.5 m | — | -81.8% | — | 0.0% | +90% / +907% |
| SRZNSurrozen, Inc. | 372.0 m | — | — | -2,885.3% | −67.4% | +91% / +340% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
1- and 3-year price returns: for PRME from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Prime Medicine is a biotechnology company developing genetic therapies based on Prime Editing, a technology that rewrites DNA without making double-stranded breaks. The company is nearing its first clinical entries for programs in Wilson disease and alpha-1 antitrypsin deficiency, and its liquidity, of $108.8 million as of June 30, 2026, provides runway into 2027, which makes the coming period decisive.
SWOT
Strengths
- Prime Editing does not require double-stranded breaks, which could reduce the risk of genomic instability compared with nucleases.
- The modular platform allows rapid swapping of the pegRNA for new mutations while keeping the same delivery system and manufacturing processes.
- The PM359 program has produced human clinical data and received several FDA designations, supporting the credibility of the technology.
Weaknesses
- The company has no product sales revenue and has reported repeated net losses since its founding.
- Financial reports flag a significant going-concern risk tied to dependence on external funding.
- Most programs are in research or preclinical stages, and the failure rate at these stages remains high.
Opportunities
- Starting clinical studies for Wilson disease and AATD could produce data that expand the evidence for in vivo Prime Editing.
- An accelerated approval path for PM359 could bring the first Prime Editing therapy to patients.
- Platform modularity could allow expansion into other liver and lung indications, as well as oncology.
Threats
- Clinical failure in the Wilson disease and AATD studies could delay or halt these programs.
- If additional funding is not available on acceptable terms, the company could be forced to reduce or eliminate programs.
- Competitors developing other gene editing technologies could reach the market first with similar therapies.
Risks
- Going concernhigh
The annual report states substantial doubt about the company's ability to continue operating without additional financing, which could affect the share price and access to capital.
- Dilution from share issuancehigh
Raising funds through share sales or convertible securities could reduce the stake of existing shareholders and impose liquidation preferences.
- Clinical riskhigh
Programs are at early stages, and results from animal models or limited studies do not guarantee efficacy in humans.
- Dependence on partnersmedium
Collaborations with Bristol-Myers Squibb and the Cystic Fibrosis Foundation could be terminated if the company fails to meet its obligations, potentially affecting funding and technology rights.
- Intellectual property disputesmedium
The arbitration with Beam Therapeutics shows that disputes over the scope of rights can be costly even when the outcome is favorable.
Investment thesis
What would need to be true (bull case)
- If clinical data from the Wilson disease and AATD studies, expected in 2027, confirm genetic correction in humans, the company could demonstrate the value of its modular platform.
- The RMAT designation for PM359 and the intention to file a BLA in 2027 could accelerate the first approval of a Prime Editing therapy.
- The favorable resolution of the arbitration with Beam Therapeutics could strengthen the company's rights over PM647.
What would break the thesis
- Limited liquidity and the going-concern warning suggest a new funding round could be needed soon, with dilution for shareholders.
- Most programs are at preclinical stage, and failure in clinical studies could sharply reduce the company's value.
- Competition in genome editing is intense, and if other technologies reach similar results faster, the advantage of Prime Editing could be diminished.
What to watch
- Initial clinical results for PM577a in Wilson disease2027
- IND and/or CTA submission for PM647 in AATDQ3 2026
- BLA submission for PM359 in CGD1H 2027
- Liquidity level and any new share issuancenext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Prime Medicine focuses its development on in vivo programs for genetic liver diseases, notably Wilson disease (PM577a) and alpha-1 antitrypsin deficiency (PM647), both based on a universal liver lipid nanoparticle. The company also has a cystic fibrosis program supported by the Cystic Fibrosis Foundation and an ex vivo program, PM359, for chronic granulomatous disease, developed with Bristol-Myers Squibb. The strategy relies on platform modularity, which allows only the mutation-specific pegRNA to change while the editor and delivery architecture stay the same. In fiscal 2025 the company had no product sales revenue, its revenue coming from collaboration and license agreements, and it reported a significant going-concern risk.
Segments
In vivo liver programs
This is the most important segment, covering Wilson disease and alpha-1 antitrypsin deficiency. For Wilson disease, an IND and a CTA have been cleared in the United States and New Zealand, while for AATD an IND and/or CTA submission is expected in the third quarter of 2026, with initial clinical data in 2027. Development in this segment is centered on what the company calls its liver franchise.
PM359 for CGD
The ex vivo program PM359 is the only one with published human clinical data and received RMAT designation from the FDA in June 2026. The company is working toward a Biologics License Application (BLA) in the first half of 2027, and it has indicated that if regulators allow an accelerated path, approval could come sooner.
Market context
Wilson disease affects an estimated 1 in 30,000 individuals across the United States, Europe and Japan, and the H1069Q mutation is most prevalent in North America and Europe. Current standard therapies, copper chelators and zinc salts, require lifelong adherence, leaving a significant unmet medical need. The market for curative genetic therapies is still early, and clinical success of the first programs could determine the pace of adoption.
Trends
- Clinical validation of gene editingtailwind
Clinical data from the PM359 program and FDA designations could support confidence among investors and partners in Prime Editing technology.
- High capital requirementsheadwind
Manufacturing genetic therapies and running clinical trials require substantial funding, and limited liquidity can force companies to issue shares or give up rights.
- Faster regulatory pathwaystailwind
RMAT, Fast Track and orphan drug designations can shorten review timelines if clinical data continue to support safety and efficacy.
- Competition in genome editingmixed
Rapid progress in CRISPR, base editing and RNA editing could reduce the differentiating advantage of Prime Editing if other approaches reach similar results.
Competitive position
Prime Medicine compares its technology with other gene editing approaches, including CRISPR nucleases, which introduce double-stranded breaks, base editors, which modify only certain substitutions, and RNA editors, which do not provide permanent correction. The company argues Prime Editing has a superior precision profile, but this advantage still needs to be demonstrated in clinical data.
In the Wilson disease market the company competes indirectly with standard treatments involving copper chelators and zinc salts, and in AATD with gene therapy approaches aimed at alpha-1 antitrypsin production. Direct competition in genome editing depends on the clinical success of each competitor's programs.
- Beam TherapeuticsBEAM
A base editing company with which Prime Medicine went through arbitration over rights to PM647; the arbitration was resolved favorably for the company, but the relationship remains important.
- Intellia TherapeuticsNTLA
A company developing CRISPR nuclease-based gene editing therapies, including liver-directed ones, offering a technologically different alternative.
- CRISPR TherapeuticsCRSP
A company developing CRISPR therapies, representing the double-strand-break approach that Prime Editing considers less precise.
- Vertex PharmaceuticalsVRTX
A company with a strong presence in cystic fibrosis that may compete in the same therapeutic area through existing or developing treatments.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report08 Jul 2026Other events
- Current report08 Jun 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement23 Apr 2026
- Current report16 Apr 2026Departure or appointment of officers
- Annual report03 Mar 2026
- Current report03 Mar 2026Results of operations · Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Prime Medicine, Inc. · 03 Mar 2026
- [2] Form 8-K, results release (exhibit 99.1) · SEC / Prime Medicine, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.